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'Pure' follicle stimulating hormone (FSH) and luteinizing
hormone (LH) are expected shortly to become available
for pharmaceutical use in the clinical setting. To test the
contribution of LH to optimal ovarian responsiveness to
FSH, 21-day-old hypophysectomized, immature, female
rats received four s.c. injections of recombinant human
LH (rhLH; total dose 1-10 IU) and/or rhFSH (total dose
30-72 IU) given at 12-hourly intervals. At 48 h after the
first injection, ovaries were removed, weighed and used to
isolate granulosa and thecal/interstitial cells for assessment
of basal and gonadotrophin-responsive steroidogenesis
in vitro, or homogenized to extract total RNA for Northern
analysis of 17-hydroxylase/Ci7_2o-lyase (cytochrome P-
450C|7a) mRNA. Serum oestradiol and uterine weight were
measured as indices of ovarian oestrogen production; and-
rostenedione was measured to reflect ovarian androgen
production. Consistent with the two-cell, two-gonadotro-
phin model of oestrogen synthesis, increased ovarian oestro-
gen secretion only occurred if both rhFSH and rhLH
were given simultaneously. Treatment with rhFSH alone
stimulated ovarian weight gain and granulosa cell
aromatase activity without oestrogen secretion, whereas
rhLH alone stimulated thecal androgen synthesis and
androgen secretion. When the total rhLH dose was fixed
at 1 IU, giving rise to an unmeasurably low serum concen-
tration of rhLH, additional treatment with rhFSH (30-72
IU) dose-dependently stimulated serum androgen concen-
trations as well as oestrogen concentrations. The -2.0 kb-
sized P-450C|7a mRNA transcript was undetectable in the
ovaries of untreated control animals but was abundant in
the ovaries of positive controls treated with 15 IU of
pregnant mare serum gonadotrophin. Treatment with 1 IU
of rhLH alone barely induced a P-450C|7a mRNA signal
and treatment with 30 IU of rhFSH alone was completely
ineffective. However, combined treatment with 1 IU of
rhLH and 30 IU of rhFSH markedly enhanced the P-
450d7a mRNA signal to a level approaching the positive-
control. Since P-450C|7ct mRNA is expressed exclusively in
thecal cells, which do not possess FSH receptors, we
conclude that (i) rhFSH upregulates thecal P-450d7a mRNA
and hence follicular androgen synthesis via granulosa-on-
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theca paracrine signalling, and (ii) tonic stimulation by
rhLH is required to facilitate thecal responsiveness to this
rhFSH-activated paracrine signal(s).
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Introduction
Urinary follicle stimulating hormone (FSH) preparations lack-
ing significant contamination with luteinizing hormone (LH)
can induce pre-oyulatory follicular development with minimal
increases in ovarian oestrogen secretion when given to patients
with World Health Organization (WHO) type I anovulatory
infertility whose endogenous LH levels are too low to measure
(Couzinet et aL, 1988; Shoham et aL, 1991). However, in
patients with detectable endogenous LH, treatment with 'pure'
FSH induces normal follicular maturation and oestrogen secre-
tion (Shoham et aL, 1994). This type of response usually
occurs when FSH is given to stimulate multiple follicular
development following pituitary desensitization with a gonad-
otrophin-releasing hormone (GnRH) agonist [e.g. in assisted
reproduction procedures (Edelstein et aL, 1990) or in patients
with WHO type II anovulatory infertility (Sagle et aL, 1991)].
It has been known for more than 50 years that both FSH
and LH are necessary to stimulate pre-ovulatory follicular
development and oestradiol synthesis (Fevold, 1941; Greep
et aL, 1942). According to the two-cell, two-gonadotrophin
model of oestrogen synthesis (Armstrong and Dorrington,
1979), FSH acts on granulosa cells to induce aromatase
(cytochrome />-450arom) activity, while LH stimulates the
formation of thecal androgens that serve as oestrogen pre-
cursors. Recently, we have demonstrated in vivo and in vitro
that FSH-induced paracrine signals from granulosa cells also
influence thecal androgen synthesis (Smyth et aL, 1993, 1994).
When pituitary-intact immature female rats were treated with
recombinant human (rh) FSH, LH-responsive thecal/interstitial
cell androgen synthesis in vitro was enhanced relative to cells
from untreated controls. Expression of thecal/interstitial 17-
hydroxylase/C17_20-lyase (cytochrome f-450C|7a) mRNA was
also markedly increased by FSH treatment in vivo. Since FSH
receptors reside exclusively on granulosa cells, this result
was interpreted as evidence of granulosa-to-theca paracrine
signalling. However, the stimulatory effect of FSH treatment
in vivo was lost if endogenous gonodotrophins were deleted
by hypophysectomy. This suggested that tonic thecal stimula-
tion by LH might be necessary for FSH-activated paracrine
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signalling to be manifest in vivo. Here we report experiments
that directly confirm this hypothesis.
Materials and methods
Human recombinant gonadotrophins
The rhFSH was GONAL-F™ (Serono Laboratories UK Ltd,
Welwyn Garden City, Herts, UK) with an in-vivo bioactivity
of 13 096 IU FSH/mg (rat ovarian weight gain assay). The
rhLH (Serono) had an in-vivo bioactivity of 13 108 IU LH/mg
(rat ventral prostate weight gain assay).
Animals and experimental design
In-vivo effects of rhFSH and rhLH were tested in female
Wistar rats hypophysectomized at 21 days of age by the
supplier (Charles River UK Ltd, Margate, Kent, UK). Gonad-
otrophin(s) was injected s.c. in 100 J-il of phosphate-buffered
saline (PBS) containing 0.1% (w/v) bovine serum albumin
(BSA) (ICN Biochemicals, High Wycombe, Bucks, UK). Four
12-hourly injections were given starting at the age of 25 days.
The treatments were rhFSH (total dose 30 or 72 IU/animal)
and/or rhLH (total dose 1 or 10 IU/animal). Negative controls
received injections of vehicle alone and positive controls
received a single injection (15 IU) of pregnant mare serum
gonadotrophin (PMSG; Sigma Chemicals Ltd, Poole, Dorset,
UK). Each experimental and control treatment group contained
at least five animals, and all experiments were done at
least twice.
Recovery of tissue and serum
Approximately 12 h after the last injection (48 h after initiating
treatment), animals were killed by carbon dioxide asphyxiation.
The ovaries and uterus were removed, dissected free of fat
and extraneous tissues and weighed on an electronic balance
(Cahn TA 4100; Cahn, Cerritos, CA, USA). Ovaries were used
to isolate thecal/interstitial cells and/or granulosa cells or
immediately snap-frozen in liquid nitrogen for isolation of
total RNA. Blood was sampled from the posterior vena cava
and allowed to clot at room temperature for 30 min. Serum
was separated and stored at — 20°C for hormone assays.
Isolation and culture ofgranulosa and thecal/interstitial cells
Granulosa and thecal/interstitial cell preparations were prepared
using previously described procedures (Miro et al., 1991;
Magoffin and Erickson, 1982). Briefly, all visible follicles
were first punctured using a 27-gauge hypodermic syringe
needle to express granulosa cells into culture medium. The
medium was M-199 (Gibco Ltd, Paisley, Renfrewshire, UK)
containing Earle's salts, 25 mM HEPES buffer, penicillin (50
IU/ml), streptomycin (50 Hg/ml) and additional (2.0 mM) L-
glutamine, supplemented with 0.1% (w/v) BSA. Cells were
then sedimented by centrifugation (5 min at 800 g), resuspended
in fresh culture medium and counted in a haemocytometer.
Cell viability, determined by staining with trypan blue, was
consistently >40%.
After eliminating as many granulosa cells as possible, the
residual ovarian tissue was rinsed in culture medium and
enzymically digested by incubation for 30 min at 37°C in
fresh medium containing 0.1% (w/v) collagenase type II from
Clostridium histolyticum (Sigma) and 0.01% DNase (Sigma).
Complete dispersal into a single-cell suspension was achieved
by repeated pipetting at the end of this incubation. The
cells were sedimented by centrifugation (5 min at 800 g),
resuspended in fresh culture medium containing 5.0% (v/v)
donor calf serum (Gibco) and counted in a haemocytometer.
Cell viability, determined by staining with trypan blue, was
consistently >90%.
Multiwell plastic culture dishes (Linbro Space Savers™
from Flow Laboratories, Rickmansworth, Herts, UK) were
inoculated with replicate 0.5 ml portions ofgranulosa or thecal
cell suspensions (40 000 cells) in culture medium. Thecal cells
were preincubated in medium containing 5.0% donor calf
serum to allow cell anchorage and recovery from the enzymic
dispersal procedure. Incubation of thecal/interstitial cells did
not measurably stimulate oestrogen production, which con-
firmed minimal contamination with granulosa cells. The pre-
incubation was for 24 h at 37°C in a humidified atmosphere
of 5% CO2/95% air. After removing the serum-containing
medium and washing the cell monolayers with 1 ml of pre-
warmed (37°C) PBS, each culture well received 0.5 ml of
serum-free medium with or without human LH (LER-1972;
5179 IU LH/mg, 2.5 IU FSH/mg) at a concentration of 10 ng/
ml. All treatments were done in triplicate.
Incubation was for 48 h at 37°C, after which the medium
was collected and stored frozen at — 20°C for subsequent
analysis of androgen content by radioimmunoassay, as
described below. The granulosa cells were incubated in 0.5 ml
of serum-free medium with or without human FSH (LER 8/
116; 900 IU FSH/mg, -0.5 IU LH/mg) at a concentration of
30 ng/ml and/or 1 (xM testosterone (Sigma). All treatments
were done in triplicate. Incubation was for 48 h at 37°C, after
which the medium was collected and stored frozen at -20°C
for subsequent analysis of oestradiol content by radioimmuno-
assay, as described below.
Androstenedione assay
The amount of androstenedione in serum and spent culture
medium was determined by radioimmunoassay (Hillier et al.,
1991b). The androstenedione antiserum was rabbit anti-androst-
4-ene-3,17-dione-7oc-carboxyethylthioether-BSA. Major cross-
reactions were androstenedione, 100%; androsterone, 46.3%;
5a-androstane-3,17-dione, 50%; testosterone, 37%; and <0.5%
for all other steroids tested. The inter- and intra-assay precision
was <15% (coefficient of variation), with a sensitivity (min-
imum detectable dose) of 0.3 nmol/1.
Oestradiol assay
The amount of oestradiol in serum and spent culture medium
was determined by radioimmunoassay (Hillier et al., 1981).
The oestradiol antiserum was donkey K3 anti-oestradiol-17-
hemisuccinyl-BSA (provided by Dr G.Read, Tenovus Institute,
Cardiff, UK). Major cross-reactions were oestradiol- 17p\
100%; oestrone, < 10%; and <0.5% for all other steroids tested.
The inter- and intra-assay precision was <15% (coefficient of
vaiation), with a sensitivity of 0.2 nmol/1.
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FSH and LH assays
rhFSH and rhLH in hypophysectomized rat serum were meas-
ured by specific immunoradiometric assays (Serono FSH
MAIAclone™ and Serono LH MAIAclone™ supplied by
Intereset, Wokingham, Berks, UK). Assay sensitivities were
0.25 mlU FSH/ml and 0.15 mlU LH/ml. Serum samples were
analysed as a single batch with an intra-assay precision of - 3 % .
Northern analysis of cytochrome P-450cl7a mRNA
Frozen tissue (whole ovaries) was homogenized in an ice-cold
solution containing 4 M guanidium thiocyanate, 24 mM sodium
citrate, 0.5% (w/v) sarcosyl and 0.1 M (3-mercaptoethanol (all
from Sigma). Total RNA was extracted with phenol-
chloroform (Chomczynski and Sacchi, 1987) and size-fraction-
ated by electrophoresis in 1.2% agarose gels containing 2.2 M
formaldehyde. RNA molecular weight markers (Gibco) were
run alongside samples on each gel and ethidium bromide
staining was used to check the uniformity of sample loading.
RNA was transferred onto nylon membranes (Hybond-N;
Amersham International, Aylesbury, Bucks, UK) in 20X
sodium citrate/sodium chloride (SSC), by capillary blotting.
cDNA probe to rat P-450cl7a mRNA (full-length cytochrome
P-450C|7a; generously donated by Dr J. Ian Mason) (Fevold
et al, 1989) was labelled with [32P]dCTP by random priming
(Megaprime kit; Amersham). Prehybridization was carried out
for 1-2 h at 42°C in 5X saline/sodium phosphate/EDTA
(SSPE), 5X Denhardt's solution, 18.5% (v/v) formamide and
0.5% (w/v) sodium dodecyl sulphate (SDS). Hybridization
was carried out overnight in the same buffer containing -1X106
cpm/ml of probe. The membranes were then washed at 65°C
for ~1 h in each of three different solutions containing 1%
SDS and decreasing salt concentrations (2X, IX and 0.5 X
SSC). The membranes were then exposed to Kodak XAR-5
for 1-3 days at —70°C using an intensifying screen.
Statistics
Analysis of variance with the Newman-Keuls test was used
to analyse differences between experimental and control obser-
vations. Differences assigned a P value of <0.05 were regarded
as statistically significant.
Results
Effect of rhFSH and rhLH administration in vivo on serum
hormone concentrations
Serum FSH, LH, oestradiol and androstenedione concentrations
in hypophysectomized immature female rats treated with
rhFSH and/or rhLH are shown in Figure 1. The circulating
FSH concentration following 48 h of treatment increased to
350-400 IU/1 following 72 IU of rhFSH (Figure la). At 1 IU
of rhLH, serum LH remained undetectable but at 10 IU of
rhLH, it rose to -17 IU/1 (Figure lb). Serum oestradiol was
unmeasurable if either rhFSH or rhLH was given alone.
However, when given in combination each gonadotrophin
dose-dependently increased oestradiol (Figure lc). Serum an-
drostenedione was increased dose-dependently by rhLH alone
(Figure Id). Treatment with 30 IU of rhFSH alone did not
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Fig. 1. Effect of treatment with recombinant human follicle
stimulating hormone (rhFSH) and/or recombinant human luteinizing
hormone (rhLH) in vivo on plasma concentrations of (a) rhFSH, (b)
rhLH, (c) oestradiol and (d) androstenedione. Hypophysectomized
immature female rats were treated with vehicle alone or rhFSH
(total dose 30-72 IU) and/or rhLH (total dose 1-10 IU) given as
four 12-hourly s.c. injections. At 48 h after beginning treatment, the
animals were killed and blood was sampled from the posterior vena
cava and analysed by specific immunoradiometric assay (rhFSH
and rhLH) or specific radioimmunoassay (oestradiol and
androstenedione). Results from a representative experiment are
expressed as mean ± SE (n S= 5). Statistics: a denotes significant
(P < 0.01) effect due to rhFSH treatment versus corresponding
treatment without rhFSH; b {P < 0.01) and c (P < 0.05) denote
significant increase due to rhLH versus corresponding treatment
without rhLH.
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stimulate androstenedione, but at 72 IU rhFSH increased
androstenedione on average 2- to 3-fold relative to control.
The lower dose of rhFSH had no effect on the androstenedione
response to 1 IU of rhLH but increased the response to 10 IU
rhLH ~2-fold; 72 IU of rhFSH increased the androstenedione
responses to both 1 and 10 IU rhLH by a similar magnitude
(Figure Id).
Effect of rhFSH and rhLH administration in vivo on ovarian
and uterine weights
Ovarian and uterine weights following treatment with a fixed
dose (30 IU) of 20 rhFSH in the presence of 1 and 10 IU
1
c
CO
a
20 1
15 "
10 -
5-
-rhLH
+ rhLH (1 IU)
+ rhLH(10IU)
ac
T
ab
/
rhLH are shown in Figure 2. Neither dose of rhLH alone
significantly affected ovarian weight. However, rhFSH alone
increased ovarian weight ~2-fold, and this response was further
enhanced by combining rhFSH treatment with either dose of
rhLH (Figure 2a). Alone, neither gonadotrophin significantly
affected uterine weight, whereas both combinations of rhLH
with rhFSH were stimulatory (Figure 2b). Use of 72 IU of
rhFSH instead of 30 IU of rhFSH caused even greater increases
in ovarian weight, without significantly affecting uterine weight
unless rhLH was also present (data not shown).
Effect of rhFSH and rhLH administration in vivo on granu-
losa cell aromatase activity in vitro
Treatment with rhFSH strongly stimulated granulosa cell
aromatase activity both in vivo and in vitro (Figure 3). The
aromatase response to combined treatment with rhFSH (30
IU) and rhLH (1 IU) was comparable with that of rhFSH
alone. Treatment with 1 IU of rhLH alone was ineffective.
Effect of rhFSH and rhLH administration in vivo on thecall
interstitial cell androgen production in vitro
In-vivo treatment with rhFSH (30 IU) or rhLH (1 IU) alone
had no significant effect on basal or LH-responsive thecal/
interstitial cell androgen production IM vitro, whereas combined
treatment with the same doses of rhFSH and rhLH in vivo led
to a markedly enhanced androstenedione response to LH
in vitro (Figure 4).
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Fig. 2. Effect of treatment with recombinant human follicle
stimulating hormone (rhFSH) and/or recombinant human luteinizing
hormone (rhLH) in vivo on (a) ovarian and (b) uterine weights.
Hypophysectomized immature female rats were treated with vehicle
alone or vehicle containing rhFSH (total dose 30 IU) and/or rhLH
(total dose 1-10 IU) given as four 12-hourly s.c. injections. At 48 h
after beginning treatment the animals were killed and the ovaries
and uteri were immediately removed and cleaned of all extraneous
material before weighing. Results from a representative experiment
are expressed as weight ± SE of a single ovary {n 3= 10), or
weight ± SE of uterine horn (« 3= 5). Statistics: a denotes a
significant (P < 0.01) increase due to rhFSH treatment versus
corresponding treatment without rhFSH; b {P < 0.01) and c (P <
0.05) denote significant increase due to rhLH treatment versus
corresponding treatment without rhLH.
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Fig. 3. Effect of treatment with recombinant human follicle
stimulating hormone (rhFSH) and/or recombinant human luteinizing
hormone (rhLH) in vivo on granulosa cell aromatase activity.
Hypophysectomized female rats were treated with vehicle alone or
vehicle containing rhFSH (total dose 30 IU) and/or rhLH (total
dose 1 IU) given as four 12-30-hourly s.c. injections. At 48 h after
beginning treatment the animals were killed and ovaries removed
for isolation of granulosa cells. Granulosa cell cultures (40 000
viable cells per well) were incubated for 48 h in serum-free
medium with 1.0 U.M testosterone (aromatase substrate) in the
presence or absence of rhFSH (30 ng/ml). Oestradiol in the spent
culture medium was determined by radioimmunoassay. Results
from a representative experiment are expressed as pmol of
oestradiol produced/1000 cells/h ± SE (n = 3). Asterisks denote a
significant difference due to rhFSH treatment in vivo versus the
corresponding untreated control (*P < 0.01; **P < 0.05).
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Effect of FSH and LH administration in vivo on ovarian P-
450cffa mRNA expression
A P-450clla mRNA signal was not detectable by Northern
analysis of ovarian total RNA from vehicle-treated control
animals (Figure 5). However, treatment with PMSG as a
positive control induced an abundant -2.0 kb-sized transcript.
Treatment with rhLH (1 IU) alone barely stimulated the
appearance of this transcript, and rhFSH (30 IU) alone was
completely negative. However, in the presence of LH, FSH
strongly increased the intensity of the P-450clya mRNA signal.
Discussion
This study using recombinant (hence 'pure') human gonadotro-
phins confirms that both FSH and LH are necessary for
fdllicular oestrogen synthesis (Fevold, 1941; Greep et ai,
1942; Armstrong and Dorrington, 1979; Mannaerts et ai,
1991). FSH treatment alone stimulates follicular growth and
increased expression of granulosa cell P-450amm (Fitzpatrick
and Richards, 1991; Whitelaw et ai; 1992), while LH acts
directly to stimulate f-450ci7c, in the theca interna (Fortune
and Armstrong, 1977; Smyth et ai, 1993). Thereby the two
gonadotrophins jointly regulate oestrogen synthesis.
A novelty here is that we have used recombinant human
gonadotrophins and hypophysectomized animals to dissect out
a paracrine (granulosa on theca) interaction that is activated
by FSH and facilitated by LH. The ovarian weight, serum
oestrogen/uterine weight and aromatase activity data presented
here are all consistent with previously reported actions of
rhFSH on ovarian oestrogen synthesis in vivo and in vitro
(Mannaerts et ai, 1991; Whitelaw et ai, 1992). rhFSH potently
stimulates ovarian weight (i.e. follicular growth) and granulosa
cell aromatase activity, but oestrogen secretion (uterine weight
gain) only occurs when LH activity is also given. rhLH alone
does not cause ovarian weight gain or oestrogen secretion but
does increase androgen secretion. Importantly, treatment with
rhFSH (devoid of LH activity, and hence unable to act directly
on thecal cells) dose-dependently increases the androgenic
response to rhLH. Since granulosa cells are the only cells in
the female body known to possess FSH receptors, this evidence
strongly suggests that FSH is able to activate a granulosa-
derived paracrine signal(s) that positively regulates thecal
androgen synthesis. Moreover, direct stimulation with rhLH
sensitizes the theca interna to this FSH-induced paracrine
signal.
Unequivocal evidence that rhLH promotes thecal/interstitial
responsiveness to rhFSH in vivo is provided by the demonstra-
tion that ovarian />-450cl7a mRNA, shown previously to be
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Fig. 4. Effect of recombinant human follicle stimulating hormone
(rhFSH) and/or recombinant human luteinizing hormone (rhLH)
administration in vivo on thecal/interstitial cell androgen production
in vitro. Hypophysectomized female rats were treated with vehicle
alone or vehicle containing rhFSH (total dose 30 IU) and/or rhLH
(total dose 1 IU) given as four 12-hourly s.c. injections. At 48 h
after beginning treatment the animals were killed and ovaries
removed for isolation of thecal/interstitial cells. The thecal/
interstitial cell cultures (40 000 viable cells per culture well) were
incubated for 48 h in serum-free medium with and without hLH
(10 ng/ml). Androstenedione in the spent culture medium was
determined by radioimmunoassay. Results from a representative
experiment are expressed as pmol androstenedione produced/
culture/48 h ± SE (n = 3). Asterisks denote significant (P < 0.01)
difference in response to LH in vitro versus any other response to
LH in vitro.
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Fig. 5. Effect of recombinant human follicle stimulating hormone
(rhFSH) and/or recombinant human luteinizing hormone (rhLH)
administration in vivo on ovarian cytochrome P-450cyja mRNA
expression in hypophysectomized female rats. The animals received
four 12-hourly s.c. injections of rhFSH (total dose 30 IU) and/or
rhLH (total dose 1 IU); negative controls received injection vehicle
alone; positive controls received a single injection (15 IU) of
pregnant mare serum gonadotrophin. Ovaries were removed 48 h
after the first injection. Total ovarian RNA was size-fractionated
(20 (Xg/track) by electrophoresis on a 1.2% agarose—formaldehyde
gel and blotted onto a nylon membrane. Upper panel: Northern
analysis using a 32P-labelled (random priming) bovine cytochrome
F-450c|7a cDNA. Exposure of the autoradiogram to Kodak XAR-5
film was for 3 days at -70°C using an intensifying screen. The -2.0
kb-sized cytochrome P-450c\ia transcript is indicated. Lower
panel: Ethidium bromide-stained 18S rRNA, illustrating sample
loading.
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located exclusively in thecal/interstitial cells (Smyth et al,
1993), is only measurably increased by treatment with rhFSH
if rhLH is given concurrently. Significantly, the dose of rhLH
required to elicit this effect in hypohysectomized immature
female rats is so low (1 IU of rhLH over 48 h) that it is not
even detectable in blood using a sensitive immunoradiometric
assay for human LH.
The nature of the paracrine signal activated by FSH is
presently unknown. However, both IGF-I (Adashi et al, 1985)
and inhibin (Hsueh et al., 1987) of granulosa cell origin
are obvious possibilities. We have previously shown that
gonadotrophin-induced oestradiol biosynthesis in individually
cultured rat follicles can be blocked by the presence of a
neutralizing antibody to inhibin (Smyth eta/., 1994). Moreover,
inhibin antibody-induced blockade of oestrogen synthesis is
overcome by the presence of exogenous aromatase substrate
(androstenedione) in the culture medium. This strongly implic-
ates inhibin in the paracrine mediation of FSH action on thecal
androgen synthesis in the rat ovary. Since FSH also stimulates
inhibin production by human granulosa cells (Hillier et al,
1991a) and inhibin promotes LH-stimulated androgen synthesis
by human thecal cells (Hillier et al, 1991b), the implications
of the present results for human reproductive physiology
seem obvious.
It is known from previous studies of LH action on gonadal
cells that < 1 % of LH receptors need to be occupied to elicit
maximal steroidogenic responses in vitro (Catt and Dufau,
1977). The present demonstration that unmeasurably low,
endogenous concentrations of LH are sufficient to facilitate
FSH-responsive ovarian androgen synthesis further emphasizes
the minimal, albeit crucial, dependence that the ovary has on
LH to undertake apparently normal rates of follicular oestrogen
synthesis.
These experimental results could have potential clinical
relevance. If they can be extrapolated to humans, they offer a
means to interpret the effects of 'pure' FSH preparations when
used to stimulate ovarian function in women with various
types of infertility, as follows.
(i) Using FSH alone in conjunction with GnRH-agonist
suppression of pituitary function to stimulate multiple follicular
development so that eggs can be collected for assisted reproduc-
tion procedures. Repeated exposure of pituitary gonadotropes
to GnRH-agonists causes 'down-regulation' involving micro-
aggregation of GnRH receptors and internalization of
agonist—receptor complexes, such that LH and FSH concentra-
tions in blood fall to near undetectable amounts. Despite a
dearth of endogenous LH, administration of 'pure' FSH alone
usually stimulates multiple follicular development and oestro-
gen secretion to degrees comparable with those achieved when
FSH and LH (i.e. human menopausal gonadotrophin) are given
simultaneously. If FSH activates a paracrine mechanism that
up-regulates LH-responsive androgen synthesis, and hence
oestradiol synthesis, it becomes evident why FSH is effective
in spite of the minimal LH concentrations present when routine
GnRH-agonist regimens are employed. It also follows that
long-term or 'deep' pituitary suppression could make patients
less responsive to FSH.
(ii) Patients with WHO group II type infertility. Women
with anovulatory infertility but who are not devoid of endogen-
ous LH often receive ovulation induction therapy, with or
without pituitary down-regulation. Such patients frequently
overrespond to FSH therapy and, if care is not taken, they can
develop ovarian hyperstimulation. Many of these women have
polycystic ovaries (PCO) associated with high basal serum LH
concentrations. Thecal cells from PCO follicles undertake
higher rates of androgen synthesis than those of 'normal'
follicles of a similar size (Gilling-Smith et al, 1993). Since
androgens enhance FSH-stimulated granulosa cell function
(including inhibin production) in vitro (Hillier et al, 1991a),
and inhibin and/or other granulosa cell factors have the
potential to promote LH-responsive thecal androgen synthesis
(Hillier et al, 1991b), reciprocal paracrine signalling between
LH-stimulated thecal cells and FSH-stimulated granulosa cells
could bring about follicular hypersensitivity to FSH.
(iii) Patients suffering from a complete LH deficiency (i.e.
WHO group I type infertility). When such patients are given
ovarian stimulation therapy, the usual aim is to induce monovu-
lation so that conception can occur in'vivo. A normal pattern
of oestrogen production is integral to a successful therapeutic
outcome. An adeqate ovarian response to 'pure' FSH therefore
requires simultaneous administration of LH, either at doses
that stimulate thecal androgen synthesis directly or in reduced
amounts sufficient to promote the indirect responsiveness of
thecal cells to FSH demonstrated here.
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